trending Market Intelligence /marketintelligence/en/news-insights/trending/mB0HnZszMu6eqvOQuSbTqw2 content esgSubNav
In This List

CSPC Pharmaceutical to commercialize another drug in US

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


CSPC Pharmaceutical to commercialize another drug in US

CSPC Pharmaceutical Group Ltd. entered an agreement to develop and commercialize another of its drug for the U.S. market.

The Chinese company engaged U.S.-based Citron Pharma Ltd. to produce, license and commercialize a "complex central nervous system generic drug" in the country.

The generic will be developed by CSPC subsidiary Conjupro Biotherapeutics Inc. with Citron Pharma handling clinical trials and regulatory approvals for distribution and sale.

Citron Pharma is required to pay up to $81.5 million to Conjupro depending on the product's application progress and amount of future sales.

Conjupro is also eligible to receive a royalty on net sales.

CSPC Pharmaceutical recently entered an agreement to commercialize its cancer drug, also in the U.S.